NewTimeSpace News: HENLIUS (02696.HK) announced on 10 July that the Phase I clinical trial application for self-developed HLX37 (recombinant humanized anti-PD-L1/anti-VEGF bispecific antibody injection) in combination with chemotherapy or HLX43 for injection (PD-L1 targeted ADC) for advanced/metastatic solid tumours has been approved by NMPA. No similar combination regimen has been approved globally to date. The Company cautions there is no guarantee of successful development and commercialisation.
NewTimeSpace News: HENGRUI PHARMA (01276.HK) announced on 10 July that it has received a Complete Response Letter (CRL) from the US FDA regarding the BLA for camrelizumab for injection combined with apatinib as first-line treatment of unresectable or metastatic hepatocellular carcinoma. The feedback mainly concerns cGMP inspection observations at the apatinib manufacturing site and does not involve clinical data, safety or efficacy issues. Final analysis of the CARES-310 trial demonstrated median overall survival of 23.8 months, the longest median OS reported for first-line liver cancer treatment to date. The Group will communicate actively with the FDA and partner Elevar Therapeutics to clarify next submission plans, while noting there is uncertainty over approval.
NewTimeSpace News: IMMUNEONCO-B (01541.HK) announced on 10 July that first patient dosing has been completed in the Phase II/III clinical trial of self-developed IMM0306 for IgG4-related disease (IgG4-RD). IMM0306 is the world’s first CD47/CD20 bispecific molecule to enter clinical development. The Company owns global intellectual property and commercialisation rights for IMM0306, while cautioning there is no guarantee of successful development or eventual launch.
NewTimeSpace News: PEGBIO CO-B (02565.HK) announced on 10 July that it has entered into a memorandum of understanding with Nasdaq-listed Rani Therapeutics Holdings, Inc. The parties intend to leverage Rani’s proprietary RaniPill® oral biologic delivery platform to develop oral formulations for multiple innovative candidates targeting obesity and metabolic disorders, pursuing formulation differentiation based on multi-target metabolic modulators and long-acting pipeline assets. The MOU is valid for three years and non-binding; formal agreements will be executed for specific projects.
NewTimeSpace News: CHINA ART FIN (01572.HK) announced on 9 July that it plans to acquire 100% issued share capital of Sande Global Investment Management Limited, a Hong Kong licensed corporation holding SFC Type 1 (Dealing in Securities), Type 4 (Advising on Securities) and Type 9 (Asset Management) licences. A non-binding letter of intent has been signed while transaction terms remain under negotiation. The Group intends to upgrade the licences for virtual asset trading services and build an innovative “Art Finance + Real World Assets (RWA)” model. The exclusivity period lasts for 60 days. If completed, the acquisition may constitute a notifiable transaction. There is no guarantee the transaction will proceed.
NewTimeSpace News: BAIYUNSHAN PH (00874.HK) announced on 9 July that Dexamethasone Sodium Phosphate Injection (1ml:5mg) manufactured by its controlled subsidiary Tianxin Pharmaceutical has passed the generic drug consistency evaluation. The domestic sales of this specification reached RMB236 million in 2025. The Group invested approximately RMB3.1678 million in relevant R&D. The approval is expected to boost product competitiveness, while uncertainties remain in production and sales.
NewTimeSpace News: Micot Pharma-B (02335.HK) announced on 9 July that the Phase II clinical trial of MT1002, the world’s first dual anticoagulant and antiplatelet peptide candidate, for anticoagulation in haemodialysis patients has completed first patient enrolment. The molecule exerts both anticoagulant and antiplatelet effects, featuring rapid onset and eliminating frequent monitoring requirements.
NewTimeSpace News: Bank of Qingdao Co.,Ltd. (03866.HK) announced on 9 July that it has completed the issuance of RMB4 billion perpetual capital bonds. The coupon rate stands at 2.01% for the first five years and will be reset every five years. Proceeds will be used to supplement the Bank’s Additional Tier 1 Capital. Bookbuilding commenced on 7 July and the issuance was finalised on 9 July.
NewTimeSpace News: CHINA-HONGKONG PHOTO PRODUCTS HOLDINGS announced on 9 July that the Board intends to nominate Mr. Chow Siu Hei as a candidate for Independent Non-executive Director at the upcoming Annual General Meeting of Shareholders. Should he be elected, he will also be appointed as a member of the Audit Committee.
NewTimeSpace News: On 9 July 2026, XPENG-W(09868.HK) saw weak performance in the afternoon session. As of 15:03, the stock was quoted at HK$51.05, down 2.11%. XPEV recently officially launched its X-Mind technical framework.
NewTimeSpace (newtimespace.com) reported that on July 9, 2026, the chip concept theme strengthened, with ASMPT(00522.HK) fluctuating higher. As of 13:30, the stock was quoted at HKD 192.000, up 3.73%.
Iluvatar CoreX proposes to place up to 14.857 million new H shares at HK$476 each, representing approximately 6.06% of existing H shares, to raise net proceeds of approximately HK$7.034 billion. Approximately 60% will be used for supply chain resilience and procurement, 15% for product iteration and next-gen R&D. The placing is expected to complete on 13 July 2026 without further shareholders' approval.
Zhipu AI proposes to place up to 19.78 million new H shares at HK$1,588 each, representing a discount of approximately 12.99% to the closing price, to raise net proceeds of approximately HK$31.375 billion. The proceeds will be used for R&D, computing resource deployment, business expansion and strategic M&A. The placing is expected to complete on 13 July 2026 without requiring further shareholders' approval.
NewTimeSpace.com reports, Pharmaron's shareholders Xinzhong Kangcheng and its concert party Xinzhong Longcheng have completed their share reduction plan, selling a total of 27.56 million shares, representing 1.50% of the company's total share capital. Post-reduction, Xinzhong Kangcheng holds 10.76% and Xinzhong Longcheng has fully exited. The reduction will not result in any change of corporate control.
By the close of trading on Jul 8, 2026, KNOWLEDGE ATLAS(02513.HK) saw a gain of 13.35% in its share price, closing at HKD 1825. During the session, it reached an intraday high of HKD 1918 and touched an intraday low of HKD 1450.
NewTimeSpace News: By the close of trading on Jul 8, 2026, EACON(07687.HK) saw a gain of 9.99% in its share price, closing at HKD 96.7. During the session, it reached an intraday high of HKD 101.2 and touched an intraday low of HKD 88.05.
